One thing that often gets unnoticed when we are looking at COVID-related surges in testing is the apparent fact that COVID has caused significant disruptions to the 'business as usual'. For example, most non-urgent surgeries and all elective procedures were cancelled due to COVID. Essential screening, such as chemistry, blood count, coag profile, etc., seems less classy, but due to high volumes, these are profitable for any pathology provider. I agree with @neoteric that revenue will normalise [even equalise] in years to come.
Ann: MAP: Sonic Investment & Partnership Investor Presentation, page-18
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$26.39 |
Change
0.580(2.25%) |
Mkt cap ! $12.67B | |||
| Open | High | Low | Value | Volume |
| $25.84 | $26.39 | $25.78 | $46.87M | 1.788M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9519 | $26.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $26.39 | 17108 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| SHL (ASX) Chart |